Do you know this(Apatinib) magical China’s domestically-made new drug?

Do you know this(Apatinib) magical China’s domestically-made new drug? 

Cancer is a major cause of death among our Chinese residents, and its morbidity and mortality have continued to rise in recent years. According to statistics, in 2016, more than 2.8 million people died of cancer in China, with an average of 7,500 people per day. Among them, the death toll from gastric cancer, lung cancer, liver cancer, esophageal cancer and colorectal cancer accounted for 3/4 of all cancer deaths. In addition, the five-year survival rate of total cancer in China is only 30.9%, which is at a low level. At the just-concluded 12th International Gastric Cancer Congress (IGCC), Professor Ji Jiafu, president of the current conference and dean of Peking University Cancer Hospital, said that there are about 680,000 new cases of gastric cancer in China each year, accounting for about half of the global incidence of cancer. It can be seen that the current situation of gastric cancer in China is very serious.

So how to solve this serious problem?

Apatinib is the world's first small molecule anti-angiogenic targeting drug that has been proven to be safe and effective in advanced gastric cancer. It is also the best single-drug after failure of standardized treatment for advanced gastric cancer. Moreover, apatinib is also the only oral drug in the treatment of gastric cancer targeted drugs, which will greatly improve the cure rate of patients. In June 2014, the clinical study of the drug was selected by the American Society of Clinical Oncology (ASCO) as the conference report. This is the first time that China's innovative drug research has been presented at the world's top academic conference and selected for the excellent study of the annual meeting.

On December 13, 2014, Jiangsu Hengrui Medicine (China) announced that apatinib, a new drug approved by the China Food and Drug Administration for the treatment of advanced gastric cancer, was officially launched in China. It can significantly prolong the overall survival of patients with advanced gastric cancer, which brings new hope for the treatment of patients with advanced gastric cancer.

As a typical representative of China's independent research and development of innovative drugs, the small molecule anti-angiogenic targeted drug apatinib obtained 49 research results in June this year, entered the annual meeting of the American Society of Clinical Oncology (ASCO2018).

At the ASCO meeting, the number of studies of apatinib was not only 2.2 times that of last year, but also covered 13 solid tumor fields including gastric cancer, colon cancer, lung cancer, liver cancer, ovarian cancer and soft tissue sarcoma, head and neck cancers. This also means a new stage in the clinical research of the innovative drug apatinib. The successful clinical research of new drugs to cancers, playing a significant role in enhancing China’s international status in the field of drug research innovation. The apatinib study covers a wide range of tumors, and the clinical results of apatinib are significant, which has aroused widespread concern and heated discussion at home and abroad.

According to reports, apatinib is a China's self-developed small molecule anti-angiogenic targeting drug for advanced gastric cancer, which blocks the oxygen and nutrient supply of tumor by highly selective inhibition of vascular endothelial growth factor receptor 2 (VEGFR-2) activity. Thereby inhibiting tumor tissue angiogenesis and achieving the purpose of killing the tumor. In the past four years, apatinib has attracted much attention in the field of gastric cancer. Nowadays, the clinical research on a variety of solid tumors by apatinib has also shown good prospects. Up to now, apatinib has more than 100 research results led by Chinese clinicians into the international academic arena such as ASCO and ESMO.